Read by QxMD icon Read


Zarine S Patel, Lauren K Hoffman, Dawn C Buse, Amy S Grinberg, Ladan Afifi, Steven R Cohen, Michelle A Lowes, Elizabeth K Seng
The original version of this article contains an error in the spelling of the title. The title should read: Pain, Psychological Comorbidities, Disability, and Impaired Quality of Life in Hidradenitis Suppurativa.
November 18, 2017: Current Pain and Headache Reports
Geraldine O'Sullivan Coyne, Therese S Woodring, Chyi-Chia R Lee, Alice P Chen, Heidi H Kong
No abstract text is available yet for this article.
November 11, 2017: Journal of Investigative Dermatology
José C Pascual, Belén Encabo, Rosa F Ruiz de Apodaca, David Romero, Juan Selva, Gregor B Jemec
No abstract text is available yet for this article.
December 2017: Journal of the American Academy of Dermatology
Victoria K Shanmugam, Shaunak Mulani, Sean McNish, Sarah Harris, Teresa Buescher, Richard Amdur
BACKGROUND: Hidradenitis supppurativa (HS) is a chronic inflammatory disease of the apocrine sweat glands affecting 1-4% of the population. While surgical excision is a mainstay of therapy, lesions often recur. Biologic therapies, including tumor necrosis factor-α and IL-12/23 inhibitors, are effective for mild to moderate HS. However, longitudinal studies investigating biologic therapy in conjunction with surgery are limited. The purpose of this analysis was to investigate impact of surgery and biologic therapy on HS disease activity...
November 11, 2017: International Journal of Dermatology
Theodora Kanni, Maria Argyropoulou, Themistoklis Spyridopoulos, Aikaterini Pistiki, Michael Stecher, Charles A Dinarello, John Simard, Evangelos J Giamarellos-Bourboulis
BACKGROUND: Patients with moderate to severe hidradenitis suppurativa (HS) failing adalimumab therapy, or those ineligible to receive it, remain a population with an unmet need. METHODS: 20 patients not eligible for adalimumab were randomized to receive 12 weeks blind treatment with placebo or MABp1, a true human antibody targeting interleukin (IL)-1alpha. HS clinical response score at week 12 was the primary endpoint. RESULTS: The primary endpoint was met in 10% and 60% of placebo- and MABp1-treated patients respectively (odds ratio 13...
November 9, 2017: Journal of Investigative Dermatology
E Delany, G Gormley, R Hughes, S McCarthy, S Kirthi, T Markham, A-M Tobin, M Murphy, B Kirby
BACKGROUND: Hidradenitis suppurativa (HS), a chronic inflammatory disease that affects apocrine gland-bearing skin, has a significant impact on patient quality of life. Estimates of the epidemiologic prevalence of HS are highly variable, and clinical data on disease characteristics and patient burden of disease remain limited. OBJECTIVE: The primary objective of this study was to determine the number of patients with HS attending dermatology clinics in a hospital setting in Ireland (within a 6-month time period)...
November 10, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
Joslyn S Kirby, Melissa Butt, Solveig Esmann, Gregor B E Jemec
Importance: Hidradenitis suppurativa (HS) places a significant burden on the health-related quality of life (HRQOL) of patients, many of whom have depression. Resilience can play a role in mitigating the negative stressors, such as the symptoms of HS, on patients' mental health. Objective: To investigate the correlation among resilience, depression, and HRQOL for patients with HS. Design, Setting, and Participants: This cross-sectional survey study of 154 patients from 2 referral centers in the United States and in Denmark was conducted from June 1, 2016, to March 31, 2017...
November 8, 2017: JAMA Dermatology
R Sabat
Acne inversa (AI)/hidradenitis suppurativa is a chronic recurrent inflammatory dermatosis with signs of a systemic disease. AI is characterized by typical skin alterations in body areas bearing apocrine glands. The care of the AI patients in Germany is still inadequate. This situation might be significantly improved through the following efforts: (i) shortening of the time between the disease onset and the diagnosis/start of therapy; (ii) the in-depth investigation of AI pathogenesis with the aim of identifying innovative therapeutic targets and blood biomarkers; (iii) establishing a method for quantifying the severity of the disease, which takes into account both the clinical assessment and objective laboratory parameters and the self-assessment of the patient (e...
November 6, 2017: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
Melody Maarouf, Ashley K Clark, Dylan E Lee, Vivian Y Shi
PURPOSE: Targeted, immune-modulating drugs are at the forefront of therapy for HS, and a comprehensive clinical trial registry is needed to facilitate data pooling and clinical efficacy comparison. MATERIALS AND METHODS: A systematic review of the database was searched for planned, in-progress, completed, or terminated trials investigating the effect of targeted biologic therapies for hidradenitis suppurativa (HS). When results of RCTs were not available, case reports or series were included...
November 10, 2017: Journal of Dermatological Treatment
J R Ingram, S Jenkins-Jones, D W Knipe, C L I Morgan, R Cannings-John, V Piguet
BACKGROUND: Epidemiology data regarding hidradenitis suppurativa (HS) are conflicting and prevalence estimates vary 80-fold, from 0.05% in a population-based study, to 4%. OBJECTIVES: To assess the hypothesis that previous population-based studies under-estimated true HS prevalence by missing undiagnosed cases. METHODS: We performed a population-based observational and case-control study using the UK Clinical Practice Research Datalink (CPRD) linked to Hospital Episode Statistics data...
November 1, 2017: British Journal of Dermatology
Zarine S Patel, Lauren K Hoffman, Dawn C Buse, Amy S Grinberg, Ladan Afifi, Steven R Cohen, Michelle A Lowes, Elizabeth K Seng
PURPOSE OF REVIEW: Hidradenitis suppurativa (HS) is a chronic, painful dermatologic disease characterized by recurrent inflammatory nodules and abscesses of intertriginous areas such as the axilla and groin. People with HS suffer from greater pain and associated psychological comorbidities, including depression, anxiety, disability, and impairments in quality of life (QoL), compared to those with other dermatologic conditions. Our review focuses on the occurrence of pain and these relationships...
November 1, 2017: Current Pain and Headache Reports
L Thorlacius, A Garg, J R Ingram, B Villumsen, P Theut Riis, Alice B Gottlieb, Joseph F Merola, Robert Dellavalle, C Ardon, R Baba, F G Bechara, A D Cohen, N Daham, M Davis, L Emtestam, P Fernandez-Penas, M Filippelli, A Gibbons, T Grant, S Guilbault, S Gulliver, C Harris, C Harvent, K Houston, J S Kirby, L Matusiak, A Mehdizadeh, T Mojica, M Okun, D Orgill, L Pallack, A Parks-Miller, E P Prens, S Randell, C Rogers, C F Rosen, S E Choon, H H van der Zee, R Christensen, G B E Jemec
BACKGROUND: A Core Outcomes Set (COS) is an agreed minimum set of outcomes that should be measured and reported in all clinical trials for a specific condition. Hidradenitis suppurativa (HS) has no agreed upon COS. A central aspect in the COS development process is to identify a set of candidate outcome domains from a long list of items. Our long list had been developed from patient interviews, a systematic review of literature and a health care professionals (HCPs) survey and initial votes had been cast in two e-Delphi surveys...
October 28, 2017: British Journal of Dermatology
Thanh-Lan Bui, Catalina Silva-Hirschberg, Josefina Torres, April W Armstrong
BACKGROUND: The relationship between hidradenitis suppurativa and diabetes mellitus is not well understood. OBJECTIVE: To compare the prevalence of diabetes mellitus between patients with and without hidradenitis suppurativa. METHODS: We conducted a systematic review and meta-analysis, which included primary observational studies that reported the prevalence of diabetes mellitus among patients with hidradenitis suppurativa in the PubMed, Embase, Cochrane Library, LILACS, and Scielo databases from 1947 to June 13, 2017...
October 19, 2017: Journal of the American Academy of Dermatology
Wayne Gulliver, Ian D R Landells, David Morgan, Syed Pirzada
Unnecessary investigations, inappropriate treatment, worsening disease, and frustration for both patients and health care professionals are the hallmarks of hidradenitis suppurativa (HS) management. In light of a new treatment algorithm and biologic therapies made available to patients, an HS model of care is outlined in this article. The recommendations and management strategy presented here have been developed to help address the currently unmet needs of this patient population. The patient-centred model of care and disease management strategies were developed through the guidance and recommendations of HS medical experts in Newfoundland and Labrador...
October 1, 2017: Journal of Cutaneous Medicine and Surgery
A R J V Vossen, H H van der Zee, E P Prens
No abstract text is available yet for this article.
October 2017: British Journal of Dermatology
(no author information available yet)
No abstract text is available yet for this article.
November 2017: Inflammatory Bowel Diseases
Rachel Giesey, Gregory R Delost, Jeremy Honaker, Neil J Korman
No abstract text is available yet for this article.
November 2017: JAAD Case Reports
P T Riis, H C Ring, R Kjaersgaard Andersen, G B Jemec
BACKGROUND: Patients with hidradenitis suppurativa (HS) often report opportunistic infections such as herpes and urinary tract infections. AIM: To compare opportunistic infections in patients with HS against a group of healthy controls (HCs). METHODS: In total, 99 patients with HS and 109 HCs were recruited at random to this retrospective case-control study. We devised a questionnaire to explore the frequency of minor infections, general practitioner (GP) visits and sick days experienced during the past 6 months...
October 10, 2017: Clinical and Experimental Dermatology
Chelsea McLellan, Mia Sisic, Hazel H Oon, Jerry Tan
BACKGROUND: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with adverse physical and psychosocial impacts. The development of an HS quality-of-life measure, HS-QoL, has been recently described. OBJECTIVE: This study was designed to validate the HS-QoL. METHOD: Fifty-five patients with HS from 4 dermatology clinics completed the 30-minute online survey. Item reduction, reliability (internal consistency), and correlation analysis (to assess convergent validity) were conducted...
October 1, 2017: Journal of Cutaneous Medicine and Surgery
Guy Shalom, Meir Babaev, Tamar Freud, Shmuel Tiosano, Nadav Pam, Amir Horev, Jacob Dreiher, Daniel A Vardy, Doron Comaneshter, Arnon D Cohen
BACKGROUND: Data on the healthcare utilization of hidradenitis suppurativa (HS) patients in primary care settings are scarce. OBJECTIVE: To investigate the healthcare service utilization of patients with HS. PATIENTS AND METHODS: In a cross-sectional study, HS patients were compared with two age- and gender-matched control groups-general population enrollees of Clalit Health Services and a group of patients with psoriasis. Healthcare services data included inpatient and outpatient community clinic visits and pharmacy claims for topical and systemic treatments...
October 5, 2017: Journal of the American Academy of Dermatology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"